About
BridgeBio Oncology develops targeted therapies for cancers driven by RAS and PI3Kα mutations, focusing on inhibiting active oncogenic states with rational drug design.
Explore BridgeBio Oncology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.